Sickle Cell Disease Treatment Market By Drug Type (Hydroxyurea, Oxybryta, Adakveo, Others), By Type (Sickle Cell Anemia, HbSC, Others), By Route of Administration (Oral, Parenteral): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global sickle cell disease treatment market was valued at $ 1,078.88 million in 2021 and is projected to reach $1,618.78million by 2031, registering a CAGR of 4.1% from 2022 to 2031.
The round and healthy red blood cells move through small blood channels to deliver oxygen to every part of the body. In sickle cell disease patients, the hemoglobin is abnormal, which causes the red blood cells get transformed into C-shaped cells called as a sickles and become hard and sticky. The symptoms of sickle cell disease includes, anemia, episodes of pain, and swelling of hands and feet.
The growth of the global sickle cell disease treatment market is majorly driven by increase in prevalence of sickle cell disease, availability of sickle cell disease medications, and initiatives taken by government to develop better healthcare infrastructure. For instance, according to Centers for Disease Control and Prevention, sickle cell disease affects 1 of every 360 African new born and 1 in 13 babies born carries the sickle cell trait.
However, high cost of treatment associated with sickle cell disease treatment and side effects associated with sickle cell disease may hinder the market growth. Conversely, expansion of R&D pipeline, ongoing medicine approvals, and strong growth potential in unexplored new markets are expected to provide numerous opportunities for the market growth during the forecast period.
The global sickle cell disease treatment market is segmented on the basis of drug type, type, route of administration, and region to provide a detailed assessment of the market. By drug type, it is segmented into hydroxyurea, oxbryta, adakveo, and others. The others segment further includes, endari, pain-relieving medication, and others.
In addition, on the basis of type is segmented into sickle cell anemia or HbSS, HbSC, and others. The others segment further includes, HbS beta thalassemia, HbSD, HbSE, and HbSO. By route of administration, it is segmented into oral and parenteral. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The key market players profiled in the report include Agios Pharmaceuticals, Bristol Myers Squibb Company, CRISPR Therapeutics, Editas Medicine, Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., Medunic USA, Inc., Novartis AG, Novo Nordisk, and Vifor Pharma.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sickle cell disease treatment market analysis from 2021 to 2031 to identify the prevailing sickle cell disease treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the sickle cell disease treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global sickle cell disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
Hydroxyurea
Distribution Channel
Hospitals Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Oxybryta
Adakveo
Others
By Type
Sickle Cell Anemia
HbSC
Others
By Route of Administration
Oral
Parenteral
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
Agios Pharmaceuticals
Bristol-Myers Squibb
CRISPR Therapeutics
editas Medicine
Emmaus Life Sciences, Inc.
Global Blood Therapeutics, Inc.
Medunic USA Inc.
Novartis AG
Novo Nordisk
Vifor Pharma
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Patent Landscape
- CHAPTER 4: SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Hydroxyurea
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
- 4.2.4.1 Hospitals Pharmacies Market size and forecast, by region
- 4.2.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region
- 4.2.4.3 Online Providers Market size and forecast, by region
- 4.3 Oxybryta
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Adakveo
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Others
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- CHAPTER 5: SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Sickle Cell Anemia
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 HbSC
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Oral
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Parenteral
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: SICKLE CELL DISEASE TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Type
- 7.2.2.1 North America Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
- 7.2.3 North America Market size and forecast, by Type
- 7.2.4 North America Market size and forecast, by Route of Administration
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Drug Type
- 7.2.5.1.2 Market size and forecast, by Type
- 7.2.5.1.3 Market size and forecast, by Route of Administration
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Drug Type
- 7.2.5.2.2 Market size and forecast, by Type
- 7.2.5.2.3 Market size and forecast, by Route of Administration
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Drug Type
- 7.2.5.3.2 Market size and forecast, by Type
- 7.2.5.3.3 Market size and forecast, by Route of Administration
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Type
- 7.3.2.1 Europe Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
- 7.3.3 Europe Market size and forecast, by Type
- 7.3.4 Europe Market size and forecast, by Route of Administration
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Drug Type
- 7.3.5.1.2 Market size and forecast, by Type
- 7.3.5.1.3 Market size and forecast, by Route of Administration
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Drug Type
- 7.3.5.2.2 Market size and forecast, by Type
- 7.3.5.2.3 Market size and forecast, by Route of Administration
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Drug Type
- 7.3.5.3.2 Market size and forecast, by Type
- 7.3.5.3.3 Market size and forecast, by Route of Administration
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Drug Type
- 7.3.5.4.2 Market size and forecast, by Type
- 7.3.5.4.3 Market size and forecast, by Route of Administration
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Drug Type
- 7.3.5.5.2 Market size and forecast, by Type
- 7.3.5.5.3 Market size and forecast, by Route of Administration
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Drug Type
- 7.3.5.6.2 Market size and forecast, by Type
- 7.3.5.6.3 Market size and forecast, by Route of Administration
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Type
- 7.4.2.1 Asia-Pacific Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
- 7.4.3 Asia-Pacific Market size and forecast, by Type
- 7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Drug Type
- 7.4.5.1.2 Market size and forecast, by Type
- 7.4.5.1.3 Market size and forecast, by Route of Administration
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Drug Type
- 7.4.5.2.2 Market size and forecast, by Type
- 7.4.5.2.3 Market size and forecast, by Route of Administration
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Drug Type
- 7.4.5.3.2 Market size and forecast, by Type
- 7.4.5.3.3 Market size and forecast, by Route of Administration
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Drug Type
- 7.4.5.4.2 Market size and forecast, by Type
- 7.4.5.4.3 Market size and forecast, by Route of Administration
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Drug Type
- 7.4.5.5.2 Market size and forecast, by Type
- 7.4.5.5.3 Market size and forecast, by Route of Administration
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Drug Type
- 7.4.5.6.2 Market size and forecast, by Type
- 7.4.5.6.3 Market size and forecast, by Route of Administration
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Type
- 7.5.2.1 LAMEA Hydroxyurea Sickle Cell Disease Treatment Market by Distribution Channel
- 7.5.3 LAMEA Market size and forecast, by Type
- 7.5.4 LAMEA Market size and forecast, by Route of Administration
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Drug Type
- 7.5.5.1.2 Market size and forecast, by Type
- 7.5.5.1.3 Market size and forecast, by Route of Administration
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Drug Type
- 7.5.5.2.2 Market size and forecast, by Type
- 7.5.5.2.3 Market size and forecast, by Route of Administration
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Drug Type
- 7.5.5.3.2 Market size and forecast, by Type
- 7.5.5.3.3 Market size and forecast, by Route of Administration
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Drug Type
- 7.5.5.4.2 Market size and forecast, by Type
- 7.5.5.4.3 Market size and forecast, by Route of Administration
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Agios Pharmaceuticals
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Bristol-Myers Squibb
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 CRISPR Therapeutics
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 editas Medicine
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Emmaus Life Sciences, Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Global Blood Therapeutics, Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Medunic USA Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Novartis AG
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Novo Nordisk
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Vifor Pharma
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 2. SICKLE CELL DISEASE TREATMENT MARKET, FOR HYDROXYUREA, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. SICKLE CELL DISEASE TREATMENT MARKET FOR HYDROXYUREA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. GLOBAL HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 5. SICKLE CELL DISEASE TREATMENT MARKET, FOR HOSPITALS PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 6. SICKLE CELL DISEASE TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. SICKLE CELL DISEASE TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. SICKLE CELL DISEASE TREATMENT MARKET, FOR OXYBRYTA, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. SICKLE CELL DISEASE TREATMENT MARKET FOR OXYBRYTA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. SICKLE CELL DISEASE TREATMENT MARKET, FOR ADAKVEO, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. SICKLE CELL DISEASE TREATMENT MARKET FOR ADAKVEO, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. SICKLE CELL DISEASE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. SICKLE CELL DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 15. SICKLE CELL DISEASE TREATMENT MARKET, FOR SICKLE CELL ANEMIA, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. SICKLE CELL DISEASE TREATMENT MARKET FOR SICKLE CELL ANEMIA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. SICKLE CELL DISEASE TREATMENT MARKET, FOR HBSC, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. SICKLE CELL DISEASE TREATMENT MARKET FOR HBSC, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. SICKLE CELL DISEASE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. SICKLE CELL DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 22. SICKLE CELL DISEASE TREATMENT MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. SICKLE CELL DISEASE TREATMENT MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. SICKLE CELL DISEASE TREATMENT MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. SICKLE CELL DISEASE TREATMENT MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 26. SICKLE CELL DISEASE TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 32. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 33. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 34. U.S. SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 35. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 36. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 37. CANADA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 38. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 39. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 40. MEXICO SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 41. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 42. EUROPE HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 43. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 44. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 45. EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 46. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 47. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 48. GERMANY SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 49. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 50. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 51. FRANCE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 52. UK SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 53. UK SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 54. UK SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 55. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 56. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 57. ITALY SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 58. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 59. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 60. SPAIN SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 61. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 62. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 64. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 69. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 70. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 71. JAPAN SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 72. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 73. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 74. CHINA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 75. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 76. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 77. INDIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 80. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 81. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 83. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 84. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 86. REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 87. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 88. LAMEA HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 89. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 90. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 91. LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 92. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 93. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 94. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 95. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 96. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 97. SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 98. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 99. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 100. SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 101. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
- TABLE 102. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 103. REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 104.AGIOS PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 105.AGIOS PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 106.AGIOS PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 107.AGIOS PHARMACEUTICALS: NET SALES,
- TABLE 108.AGIOS PHARMACEUTICALS: KEY STRATERGIES
- TABLE 109.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
- TABLE 110.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
- TABLE 111.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
- TABLE 112.BRISTOL-MYERS SQUIBB: NET SALES,
- TABLE 113.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
- TABLE 114.CRISPR THERAPEUTICS: COMPANY SNAPSHOT
- TABLE 115.CRISPR THERAPEUTICS: OPERATING SEGMENTS
- TABLE 116.CRISPR THERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 117.CRISPR THERAPEUTICS: NET SALES,
- TABLE 118.CRISPR THERAPEUTICS: KEY STRATERGIES
- TABLE 119.EDITAS MEDICINE: COMPANY SNAPSHOT
- TABLE 120.EDITAS MEDICINE: OPERATING SEGMENTS
- TABLE 121.EDITAS MEDICINE: PRODUCT PORTFOLIO
- TABLE 122.EDITAS MEDICINE: NET SALES,
- TABLE 123.EDITAS MEDICINE: KEY STRATERGIES
- TABLE 124.EMMAUS LIFE SCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 125.EMMAUS LIFE SCIENCES, INC.: OPERATING SEGMENTS
- TABLE 126.EMMAUS LIFE SCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 127.EMMAUS LIFE SCIENCES, INC.: NET SALES,
- TABLE 128.EMMAUS LIFE SCIENCES, INC.: KEY STRATERGIES
- TABLE 129.GLOBAL BLOOD THERAPEUTICS, INC.: COMPANY SNAPSHOT
- TABLE 130.GLOBAL BLOOD THERAPEUTICS, INC.: OPERATING SEGMENTS
- TABLE 131.GLOBAL BLOOD THERAPEUTICS, INC.: PRODUCT PORTFOLIO
- TABLE 132.GLOBAL BLOOD THERAPEUTICS, INC.: NET SALES,
- TABLE 133.GLOBAL BLOOD THERAPEUTICS, INC.: KEY STRATERGIES
- TABLE 134.MEDUNIC USA INC.: COMPANY SNAPSHOT
- TABLE 135.MEDUNIC USA INC.: OPERATING SEGMENTS
- TABLE 136.MEDUNIC USA INC.: PRODUCT PORTFOLIO
- TABLE 137.MEDUNIC USA INC.: NET SALES,
- TABLE 138.MEDUNIC USA INC.: KEY STRATERGIES
- TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 142.NOVARTIS AG: NET SALES,
- TABLE 143.NOVARTIS AG: KEY STRATERGIES
- TABLE 144.NOVO NORDISK: COMPANY SNAPSHOT
- TABLE 145.NOVO NORDISK: OPERATING SEGMENTS
- TABLE 146.NOVO NORDISK: PRODUCT PORTFOLIO
- TABLE 147.NOVO NORDISK: NET SALES,
- TABLE 148.NOVO NORDISK: KEY STRATERGIES
- TABLE 149.VIFOR PHARMA: COMPANY SNAPSHOT
- TABLE 150.VIFOR PHARMA: OPERATING SEGMENTS
- TABLE 151.VIFOR PHARMA: PRODUCT PORTFOLIO
- TABLE 152.VIFOR PHARMA: NET SALES,
- TABLE 153.VIFOR PHARMA: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.SICKLE CELL DISEASE TREATMENT MARKET SEGMENTATION
- FIGURE 2.SICKLE CELL DISEASE TREATMENT MARKET,2021-2031
- FIGURE 3.SICKLE CELL DISEASE TREATMENT MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.SICKLE CELL DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.PATENT ANALYSIS BY COMPANY
- FIGURE 13.PATENT ANALYSIS BY COUNTRY
- FIGURE 14.SICKLE CELL DISEASE TREATMENT MARKET,BY DRUG TYPE,2021(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HYDROXYUREA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OXYBRYTA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ADAKVEO SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 19.SICKLE CELL DISEASE TREATMENT MARKET,BY TYPE,2021(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SICKLE CELL ANEMIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HBSC SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHERS SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 23.SICKLE CELL DISEASE TREATMENT MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ORAL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF PARENTERAL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031(%)
- FIGURE 26.SICKLE CELL DISEASE TREATMENT MARKET BY REGION,2021
- FIGURE 27.U.S. SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 28.CANADA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 29.MEXICO SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 30.GERMANY SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 31.FRANCE SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 32.UK SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 33.ITALY SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 34.SPAIN SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 35.REST OF EUROPE SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 36.JAPAN SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 37.CHINA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 38.INDIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 39.AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 40.SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 41.REST OF ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 42.BRAZIL SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 43.SAUDI ARABIA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 44.SOUTH AFRICA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 45.REST OF LAMEA SICKLE CELL DISEASE TREATMENT MARKET,2021-2031($MILLION)
- FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 50.COMPETITIVE DASHBOARD
- FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 52.AGIOS PHARMACEUTICALS.: NET SALES ,($MILLION)
- FIGURE 53.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)
- FIGURE 54.CRISPR THERAPEUTICS.: NET SALES ,($MILLION)
- FIGURE 55.EDITAS MEDICINE.: NET SALES ,($MILLION)
- FIGURE 56.EMMAUS LIFE SCIENCES, INC..: NET SALES ,($MILLION)
- FIGURE 57.GLOBAL BLOOD THERAPEUTICS, INC..: NET SALES ,($MILLION)
- FIGURE 58.MEDUNIC USA INC..: NET SALES ,($MILLION)
- FIGURE 59.NOVARTIS AG.: NET SALES ,($MILLION)
- FIGURE 60.NOVO NORDISK.: NET SALES ,($MILLION)
- FIGURE 61.VIFOR PHARMA.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook